Diligence memo · auto-generated · as of July 2, 2026
Immunis, Inc.
Immunis, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Immunis, Inc. operates in Biotechnology, based in Laguna Beach.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immunis, Inc. has raised $20M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2024-06-17.
Most recent recorded round closed around 2024-06-17.
Valuation (modeled)modeled
Provath models Immunis, Inc. at approximately $148M (range $41M–$267M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.88× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era. Within the normal band (88% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.0 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 68% of Biotechnology peers (4293 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.